Introduction -- Anorexia Nervosa
================================

Anorexia nervosa (AN) is a complex psychiatric disorder affecting around 1% of females and 0.1% of males, of which as many as 10% die as a result of the disorder ([@B7]; [@B40]; [@B60]). The diagnostic criteria, according to the Diagnostic and statistical manual of mental disorders (DSMV), include persistent food intake restriction leading to significantly low body weight, combined with persistent behaviors that interfere with weight gain, and body image distortion ([@B67]). One central and yet unexplained part of AN is the contradictory response to negative energy balance and the inability to ingest adequate energy, leading to severe underweight. It is indeed paradoxical that while most individuals quickly regain the weight lost from dieting ([@B61]), individuals with AN stay in an emaciated state commonly for many years, some even until death. It has been speculated that hunger signals are diminished or even absent in individuals with AN, and that satiety signals on the other hand are exaggerated ([@B14]; [@B59]). Supporting this hypothesis, a genome wide association study (GWAS), as well as genetic correlation data, indicate that individuals with AN are genetically predisposed to a lower body weight set point ([@B16]; [@B26]). However, in order to understand the complex biology of AN, in particular the illogical response to starvation and underweight, we need to learn more about the neurobiological pathways and molecular mechanisms that are associated with severe dysregulation of food intake. This is something that is technically difficult and to some extent impossible to do in humans, since post-mortem tissues rarely are available. On the other hand, animal models cannot capture all aspects of AN but they are able to mirror the core features of the disorder e.g., elective starvation, emaciation and premature death ([@B72]). Animal models have therefore proved to be invaluable resources for researchers in the field. One such model is the *anx/anx* mouse.

The *anx/anx* Mouse
===================

The homozygous *anx*-mouse appears normal at birth, meaning that it is indistinguishable from their homozygous and heterozygous wildtype (wt) siblings. However, during the first postnatal weeks they gradually develop the core symptoms of AN; starvation and emaciation ([Figure 1](#F1){ref-type="fig"}). The *anx/anx* mouse dies prematurely around 3 weeks of age, and by then weigh around half as much as their siblings. They are able to eat, but despite full access to milk from the mother, eat significantly less already from postnatal day (P) 5. Worth to note is that the diurnal patterns in food intake seen in their healthy siblings are mirrored in the *anx/anx* mouse, even though the amount ingested is significantly smaller ([@B48]). Neurological/behavioral deviations such as head weaving, hyperactivity, body tremors and uncoordinated gait, were described in the original paper by [@B48]. When corrected for body weight, brain and thymus weights are increased compared to their healthy siblings, both at P5 and P15, while the weight of spleen is reduced ([@B48]). See [Table 1](#T1){ref-type="table"} for a summary of the aberrances in the *anx/anx* mouse discussed here and below.

![An *anx/anx* mouse and wildtype (+/+) littermate, age 17 days.](fnins-13-00059-g001){#F1}

###### 

Main characteristics of the *anx/anx* mouse.

  Aberrances of the *anx/anx* mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Reference
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  **Major phenotypes:** reduced food intake, emaciation and premature death.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     [@B48]
  **Organ changes:** increased weight of thymus and brain, and reduced weight of spleen.                                                                                                                                                                                                                                                                                                                                                                                                                                                         [@B48]
  **Behavioral/Neurological phenotypes:** head weaving, tremor, hyperactivity and uncoordinated gait.                                                                                                                                                                                                                                                                                                                                                                                                                                            [@B48]
  **Hypothalamic neuropeptidergic/-transmitter and molecular aberrances:** *- AGRP/NPY*: increased number of AGRP/NPY-immunopositive cell bodies in Arc, reduced number of immunopositive projections. N.C /reduced mRNA expression of AGRP and NPY in Arc. *- POMC/CART*: Reduced number of CART-immunopositive cell bodies in Arc, DMH, LHA, reduced number of immunopositive projections in Arc. Reduced number of Y1-immunopositive cell bodies and projections. Reduced POMC mRNA in Arc. - Increased hypothalamic expression of *Ntrk3*.   [@B5]; [@B56] [@B31]; [@B21] [@B33] [@B4]; [@B58] [@B51]
  **Hypothalamic inflammation**, e.g., microglia activation and expression of MHC class I by hypothalamic microglia.                                                                                                                                                                                                                                                                                                                                                                                                                             [@B44]; [@B50]; [@B56]
  **Hypothalamic degeneration**, e.g., expression of MHC class I by Arc neurons, microglia-associated cell death, increased TUNEL labeling in Arc.                                                                                                                                                                                                                                                                                                                                                                                               [@B58]
  **Mitochondrial dysfunction**, e.g., down regulation of *Ndufaf1* and reduced capacity of CI.                                                                                                                                                                                                                                                                                                                                                                                                                                                  [@B46]
  **Neurotransmitter changes in other parts of the brain:** - Increased apoptosis and proliferation in hippocampus. - Serotonergic hyperinnervation of hippocampus, striatum, cortex and cerebellum. - Altered dopaminergic neurotransmission.                                                                                                                                                                                                                                                                                                   [@B42] [@B74] [@B35]
  **Pancreatic aberrances**, e.g., glucose intolerance, reduced insulin release and inflammation.                                                                                                                                                                                                                                                                                                                                                                                                                                                [@B45]
  **Reduced hypothalamic metabolism**, e.g., reduced glucose uptake, lactate and activation of AMPK, and increased PCr.                                                                                                                                                                                                                                                                                                                                                                                                                          [@B3]
  **Changes in serum metabolites**, i.e., reduced leptin and increased FFA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      [@B33]; [@B45]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

AGRP, agouti-gene related protein; AMPK, AMP-activated kinase; Arc, the Arcuate nucleus; CI, complex I of the oxidative phosphorylation system; CART, cocaine and amphetamine-regulated transcript; DMH, the dorsomedial hypothalamic nucleus; FFA, free fatty acids; LHA, the lateral hypothalamic area; MHC class I, major histocompatibility complex I; N.C, no change;

Ndufaf1

, The NADH dehydrogenase (ubiquinone) 1a-subcomplex gene; NPY, neuropeptide Y;

Ntrk3

, neurotrophic receptor kinase 3 gene; PCr, phosphocreatine; POMC, pro-opiomelanocortin; TUNEL, terminal dUTP nick end labeling; Y1, neuropeptide Y receptor 1.

The *anx* Mutation
------------------

The *anx* mutation arose spontaneously at the Jackson laboratory in Bar Harbor, Maine, already in 1976 in the F2 generation of a cross between DW/J and an inbred strain, the latter was derived from a cross between M.m.poschiavinus and an inbred Swiss strain. The male *anx* carrier was crossed to a female B6C3H-a/a F1 mouse, and the mutation has since then been conserved on this background ([@B48]). We have mapped the mutation to a 0.2 cM interval residing between the markers D2Mit133 and Jojo5 chromosome 2 (Chr 2: bp 118, 889, 896--120, 175, 108^[1](#fn01){ref-type="fn"}^) ([@B46]). So far, no sequencing attempts have been able to show any unique sequence alteration. However, one needs to keep in mind that the background of the *anx/anx* mouse includes five different strains (see above) which makes *de novo* assembly difficult. The lack of unique finding could also mean that the mutation is located in a regulatory element outside the interval. The NADH dehydrogenase (ubiquinone) 1a-subcomplex (*Ndufaf1*) gene, shown to be closely associated with several of the *anx/anx* phenotypes, is however, located in the short interval of the mutation (see section on mitochondrial dysfunction below) ([@B46]). *Ndufaf1* is an assembly factor for complex I (CI) in the mitochondrial oxidative phosphorylation system (OXPHOS) ([@B82]). In addition, work by [@B41] identified a point mutation in *Tyro3* which they conclude is not the *anx*-mutation but a strain specific modifier of *anx*-phenotypes ([@B41]). Thus, despite that the *anx/anx* mouse model recently turned 40 years, the mutation is still unknown. Hopefully modern techniques within e.g., sequencing will be able to shed light on this mystery.

Neurochemistry of the *anx/anx* Mouse
-------------------------------------

Several changes in neuropeptidergic and -transmitter systems, in particular systems in the hypothalamus known to regulate food intake and metabolism (energy homeostasis), have been documented in the *anx/anx* brain ([@B6], [@B4]; [@B33], [@B34]; [@B57]). A part of the hypothalamus, called the Arcuate nucleus (Arc), is of particular importance concerning energy homeostasis. The Arc harbors among others a neuronal population co-expressing two orexigenic neuropeptides; agouti-gene related protein (AGRP) and neuropeptide Y (NPY), and a neuronal population co-expressing the anorexigenic peptide/precursor; pro-opiomelanocortin (POMC) and cocaine and amphetamine-regulated transcript (CART) ([@B9]; [@B10]; [@B70]). Aberrances have been documented in both these neuronal populations in the *anx/anx* mouse. Immunohistochemistry revealed increased number of NPY and AGRP immunopositive cell bodies within the Arc, combined with a reduction in AGRP/NPY immunopositive projections in the hypothalamic and extra-hypothalamic target areas of these neurons ([@B6], [@B5]; [@B21]; [@B56]). *In situ* hybridization studies have with regard to these neuropeptides been inconsistent, which most likely is attributed to overexposure of the labeled glass slides in the earlier studies. Thus, while initial studies documented no change in mRNA levels of NPY in the Arc of the *anx/anx* mouse ([@B6]; [@B31]), a later study showed increased mRNA for both NPY and AGRP in the *anx/anx* Arc ([@B21]). With regard to the POMC/CART population, significantly decreased levels of CART mRNA, as well as CART immunopositive cell bodies and fibers in Arc have been shown in the *anx/anx* hypothalamus. Also, a lower number of detectable CART-expressing cells in the dorsomedial hypothalamic nucleus/lateral hypothalamic area is seen ([@B33]). *In situ* hybridization demonstrated decreased numbers of POMC-expressing neurons in the *anx/anx* Arc ([@B4]). Using the neuropeptide Y receptor 1 (Y1) which outlines the soma and dendrites of POMC/CART neurons ([@B88]; [@B43]), markedly reduced immunoreactivity in Arc and the paraventricular nucleus of hypothalamus was revealed ([@B4]; [@B58]). Clinically, genetic variants of AGRP have been associated with AN ([@B13]) or with lowest BMI during AN illness ([@B87]). Increased plasma levels of the peptide have been documented in AN ([@B54]), but it is so far unknown if this change remains after weight recovery. The changed cerebrospinal fluid levels of NPY seen in AN is however, known to be secondary to the illness ([@B22]).

In addition, an increased expression of the neurotrophic receptor kinase 3 (*Ntrk3)* gene has been shown in the *anx/anx* hypothalamus ([@B51]). This agrees with AN being associated with specific variants of the genes for brain derived neurotrophic factor (BDNF) and neurotrophic receptor tyrosine kinase 2 (NTRK2) ([@B65], [@B66]).

Changes have been documented also in other brain regions than the hypothalamus. Increased apoptosis and proliferation in the dentate gyrus of the hippocampus ([@B42]), serotonergic hyperinnervation in hippocampus, cortex, olfactory bulb and cerebellum ([@B74]), as well as altered dopaminergic transmission in the striatum ([@B35]), have been demonstrated. Genetic variants as well as deviant levels of metabolites and receptors related to dopamine and serotonin have been linked to the AN pathology ([@B39], [@B38]; [@B37]).

Neuroinflammation and Degeneration in the anx/anx Hypothalamus
--------------------------------------------------------------

The hypothalamic neurochemical aberrances of the *anx/anx* mouse are accompanied by signs of inflammation and degeneration ([@B44]; [@B50]; [@B56], [@B58]). Microglia cells are immunocompetent cells that are activated in the central nervous system in response to e.g., inflammation, neurodegeneration or injury ([@B55]; [@B75]). In the *anx/anx* brain, microglia are activated selectively in the hypothalamic regions where the neurons, both cell bodies and projections, expressing the orexigenic neuropeptide AGRP are located ([@B56]). The first appearance of activated microglia overlaps in time with the loss of AGRP immunoreactive projections, i.e., P12--15 ([@B56]). Similarly, chemical ablation of the AGRP neurons results in starvation in both normal weight and obese mice, and results in glia (microglia and astroglia) activation in the target areas ([@B85], [@B86]). Major histocompatibility complex I is expressed by the activated microglia, but also by the AGRP and POMC expressing neurons in the *anx/anx* brain ([@B58]). This latter finding combined with increased hypothalamic terminal dUTP nick end labeling (TUNEL) labeling and so called microglia-associated cell death ([@B64]), made us conclude that hypothalamic degeneration is associated with the anorexia of the *anx/anx* mouse ([@B58]). In addition, two microarray studies of the *anx/anx* hypothalamus revealed changed expression of an enrichment of genes involved in inflammation and cell death ([@B44]; [@B50]). While it is unknown if hypothalamic inflammation occurs in AN, it has been linked to cachexia, the anorexia that often accompanies chronic illnesses such as cancer and HIV ([@B18]; [@B19]).

Mitochondrial CI Dysfunction and Reduced Hypothalamic Metabolism
----------------------------------------------------------------

A dysfunction selective of CI in OXPHOS, and subsequent increased oxidative stress, have been revealed in the hypothalamus of the *anx/anx* mouse ([@B46]). This CI dysfunction is connected to down regulation of the gene *Ndufaf1* which in fact is located in the *anx* interval (see section on the *anx* mutation above). The down regulation has been confirmed at the protein level at P21 ([@B46]). *Ndufaf1* encodes one of several proteins crucial for the correct assembly of the 44--46 proteins that build up CI ([@B73]; [@B77],[@B78]; [@B24]). Selective neuronal damage and glia activation, as shown in the *anx/anx* mouse ([@B56], [@B58]), has been shown in another animal model with CI deficiencies, i.e., the Ndufs4-KO mouse ([@B63]). The NDUFAF1 gene, as well as other players in CI biogenesis, have been implicated in human pathology; resulting in e.g., leukodystrophy and failure to thrive in young children ([@B82], [@B83]; [@B17]; [@B15]). In fact, CI dysfunction has been shown in leukocytes from patients with AN ([@B81]), but it remains to be explored if this is a cause or consequence of the disorder. This far, the NDUFAF1 gene has not been associated with AN, but it would be worth exploring genetics variants related to OXPHOS function and a potential association with AN, similar to what has been shown in other psychiatric disorders e.g., autism spectrum disorder ([@B23]). With this saying the *anx/anx* model is a model of value for research on all human conditions with loss of appetite i.e., anorexia, including the anorexia seen in cachexia and failure to thrive, as well as AN. The *anx/anx* mouse is unique in the sense that few other models exist were the mice, similarly to the human conditions just mentioned, eat insufficient despite having full access to food. This in contrast to models were the researcher in one way or another limits the access of food ([@B72]).

Diseases associated with mitochondrial dysfunction are commonly associated with a stressed metabolic profile, and hypermetabolism ([@B84]; [@B32]; [@B53]). Supposedly such metabolic responses occur in order to safeguard adequate levels of ATP. In some cases, conversely, mitochondrial dysfunction is associated with reduced glucose uptake and hypometabolism, e.g., in Alzheimer's disease and epilepsy ([@B8]; [@B76]). This resembles what we saw in the *anx/anx* hypothalamus, i.e., lower glucose uptake rate, decreased lactate content, as well as elevated phosphocreatine (PCr) content and reduced activation of AMP-activated kinase (AMPK) in the basal state ([@B3]). This is similar to the hypometabolic state seen in hibernation ([@B25]) and could be reflecting lower neuronal activity ([@B11]). Different neuronal populations respond differently to this type of metabolic stress ([@B69]), which has been ascribed to the subtype of ATP-sensitive potassium channel (K-ATP) they express. A specific subtype of K-ATP channel that consists of Kir 6.2 and SUR1 subunits becomes activated by mitochondrial CI dysfunction, i.e., by increased ROS levels and/or reduced levels of ATP. This leads to ceased electrical activity, hyperpolarization and reduced firing, in a means of protecting the cell from the energy deficiency and increased oxidative stress ([@B47]). Kir6.2/SUR1 K-ATP channels are expressed by the hypothalamic POMC/CART and AGRP/NPY neurons, and by a limited number of other cell populations including the pancreatic beta-cells and dopaminergic neurons in Substantia Nigra ([@B52]; [@B29]; [@B80]; [@B79]). Firing of action potentials and release of neurotransmitters are processes that require high amounts of energy. Therefore, inhibition of these processes would conserve energy during conditions when energy is scarce ([@B2]; [@B71]). In addition, uncontrolled generation of ROS, commonly accompanying CI dysfunction, can also cause diminished firing of the AGRP/NPY neurons, thus resulting in a reduced orexigenic drive ([@B1]; [@B27]).

Pancreatic Dysfunction and Aberrant Levels of Fat Derived Molecules
-------------------------------------------------------------------

The *anx/anx* mouse also displays a pancreatic dysfunction ([@B45]). More specifically, they are markedly glucose intolerant, and show reduced insulin release upon glucose tolerance test. This is associated with elevated serum concentrations of free fatty acids (FFAs) in the *anx/anx* mouse and increased macrophage infiltration \[indicative of inflammation ([@B30]; [@B36])\] of *anx/anx* islets. Increased levels of FFAs have been connected to inhibition of glucose-induced insulin secretion ([@B20]). Interestingly, isolated *anx/anx* islets cultured in the absence of FFAs show increased insulin release upon glucose stimulation and show no signs of inflammation. Thus, the diabetic phenotype of the *anx/anx* mouse seems to be related to the elevated FFAs and inflammation in pancreatic islets. This finding is interesting in the light of the increased incidence of eating disorders that has been reported in young women with diabetes ([@B28]; [@B49]), and documented increased levels of circulating FFAs in AN ([@B62]; [@B12]). Also similar to individuals with AN, the *anx/anx* mouse has low levels of the fat derived and food intake regulating hormone leptin, and high levels of cholesterol in serum ([@B48]; [@B68]).

Conclusion and Future Perspective
=================================

The *anx/anx* mouse shares several characteristics with patients with AN, including emaciation, starvation, premature death, diabetic features, increased FFA and low leptin, and is therefore a unique and very valuable resource in order to explore and understand the (neuro)biology of AN. Future research should explore if hypothalamic inflammation and/or degeneration, as seen in the *anx/anx* mouse, are mechanisms involved also in AN. Further studies are also needed in order to clarify if the mitochondrial dysfunction seen in AN ([@B81]) is a cause or consequence of the disorder. Finally, it would be of value to be able to define the *anx*-mutation, as well as explore other brain areas related to food intake regulation, e.g., nucleus tractus solitarius and the parabrachial nucleus in the *anx/anx* mouse.
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